RD General Agenda Topics – September 16, 2021

Briefings for Michal

- PRIA/registration overview 2/23rd (complete)
- Dicamba 2/18th (complete)
- Sulfoxaflor 3/4th (complete)
- Pet incidents 3/31st (complete)
- FDA/EPA jurisdiction 4/12th (complete)
- SW2 revocation options 5/3rd (complete)
- Antibiotics 5/17th (complete)

Waiting for OPP-IO

- Kaput Feral Hog Bait petition response
- RD workload analysis – action items/next steps – email
- Cycalniliprole/flonicamid FD first residential new use **PRIA date 9/20th**

New Active Ingredients (include original PRIA date)

- Tetraniliprole – completed!
- Broflanilide – completed!
- Picarbutrazox – completed!
- Fluxametamide – completed!
- Fluindapyr – completed!
- Trifludimoxazin – completed!
- Ipflufenoquin – PD published 6/25. PRIA date **10/29/21** (Original PRIA date 4/19/21) (FB).
- Rekleml – PD published 7/23. PRIA date **10/5/21** (Original PRIA date 4/19/21) (IVB3).
- Isoprothiolane – Import tolerance. PRIA date 10/12/21 (Original PRIA date 10/12/21) (FB)
- Pyflubumide – Import tolerance pilot. PRIA date 12/20/21 (Original PRIA date 12/20/21) (IVB1).
- Florylpicoxamid – working with company on ESA mitigation/ partial effects finding. PRIA date **10/27/21** (Original PRIA date 10/27/21)
- Pyraclonil – working with company on ESA mitigation/CA only rice. PRIA date **11/22/21**. (Original PRIA date 11/22/21)
- L-Glufosinate Ammonium – Risk Assessment phase. PRIA date 10/12/2021 (FHB). ESA issue. Moving forward with incorporating ESA analysis. Will require lengthy renegotiation per briefing with Ed; companies have been notified.

Other Chemical Actions

- Dicamba
  - Bayer and BASF requesting feedback on pending pre-mixes; sent 75 day letters
  - USDA conducting EIS (instead of EA) on dicamba resistant corn; issued a 60-day public comment period 5/8th; Comment period extended to 6/28. Coordinating with AO's OP and regions;
  - **24 (c)s –**

- NC – denial 3/15th, TN – denial 4/9th, GA – denial 4/23rd, TX – Notice of intent to deny signed 6/15th; TX withdrew, KS – request withdrawn, MS – no formal request following pre-consultation discussions
- **AAPCO letter to Administrator** – rec'd 7/14, met with AAPCO Board 9/9th, de-brief with Ed and Jake

- **2021 incidents:**
  - Met with WSSA (8/30) and AAPCO (9/1)
  - Sent 6(a)(2) letters 9/9th – Bayer, BASF, Syngenta, Corteva;
  - Corteva requesting extension to 10/12th
  - Bayer requesting extension to 10/5th – Bayer meeting 9/22nd
  - BASF plans to submit on time – planning to come in the 1st week of October

- **Antibiotics** – will need to brief the new team (FB)
  - Briefed Michal 5/17th; Received policy feedback on the antibiotic issue;

Ex. 5 Deliberative Process (DP)

- **Cyclaniliprole/flonicamid** –first residential use; public process; FD – with the OPP-IO
- **Seresto** – pet collar with high rate of incidents (death and neuro); press inquiries; 6a2 letter sent; received information from Elanco; team is meeting with FDA 9/16th. FOIA issue; press inquiry
- **Aldicarb** – court vacated; RD will issue cancellation order working with OGC

Ex. 5 Deliberative Process (DP)

Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction – Michal follow up complete; team identified appropriate "model" MOUs and sent talking points; Ed connected with Dr. Solomon – FDA/EPA confusion
- COVID-19 Activities – Sect 18s –
  - SW2 – revocation of existing AR, TX S18s based on science and violations – completed!
  - Grignard – (NV, PA, TX, MD; amendment to TN and GA) – completed!
  - Kraton – completed!
  - Ionopure Air – risk issues
  - Acteev Facemasks
- OIG Audits
  - dicamba/science integrity
  - MP3 oversight – corrective action on recommendation 5 (revise NPMG guidance) completed June 30, 2021; Case close out complete
  - 24c audit – corrective action on recommendation 5 (contact state partners on pre-submission consultation options) completed June 2021;

Ex. 5 Deliberative Process (DP)

- **PFAS** – pyrifluqyinazon first residential use PD; classified as PFAS according to OPPT definition
- **Inert** – Fragrance petition (Pat Quinn) – 2 petition responses scheduled for OGC review in June (Kerry); other petition responses will follow within existing resource constraints

- **CRP** (Child resistant Packaging) testing – industry has requested flexibilities in testing requirements due to COVID impacts; CPSC (whose regulations we use) have issued similar flexibilities. Team recommends issuing some but not all flexibilities. Next steps- COVID workgroup

International/Stakeholders

- SFIREG (dan)

Business/process/technology

- ISB – FEP/21-day backlog:
  - backlog addressed by end of April; RD SWAT team addressing newer receipts
  - RD SWAT actions - completed!
- eCSF/OPPEL – eCSF May 9th soft launch; OPPEL -TBD
- RD workload analysis – any additional feedback; see meeting summary and action items.
- SF/OPPIN issue in reassigning cases from RD to AD

Speaking Engagements –

People/Personnel/Resources

Ex. 5 Deliberative Process (DP)

CA topics (Karen Morrison):

- Missing environmental hazard statements – RD BC's are generating a response